Madrigal Pharmaceuticals Initiates Rolling Submission of New Drug Application for Resmetirom to FDA for NASH Treatment

Madrigal Pharmaceuticals, Inc. has announced the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of its drug resmetirom for the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. The company expects to complete the full submission of the NDA in July 2023. &nbsp Resmetirom was granted Breakthrough Therap..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 2.
  • textsms

AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination

AEON Biopharma and Priveterra have announced the arrangement of up to $125 million in financing for their proposed business combination. The funding includes $50 million from existing and new AEON investors, as well as cash from Priveterra's trust account. This funding will allow AEON to continue its development of a botulinum toxin complex for the treatment of medical conditions, including migr..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 2.
  • textsms